Stockscreener 앱 받기
1.55
16.67%
-0.31
시간 외 거래:
1.55
전일 마감가:
$1.86
열려 있는:
$1.715
하루 거래량:
119.49K
Relative Volume:
0.12
시가총액:
$1.05M
수익:
$1.22M
순이익/손실:
$-3.26M
주가수익비율:
-0.2522
EPS:
-6.1455
순현금흐름:
$-6.38M
1주 성능:
-0.64%
1개월 성능:
-46.18%
6개월 성능:
-76.87%
1년 성능:
-88.43%
1일 변동 폭
$1.55
$1.73
1주일 범위
$1.55
$2.08
52주 변동 폭
$1.43
$16.30
Scinai Immunotherapeutics Ltd Adr Stock (SCNI) Company Profile
명칭
Scinai Immunotherapeutics Ltd Adr
전화
972-8-9302529
주소
JERUSALEM BIOPARK, 2ND FLOOR, JERUSALEM
Compare SCNI vs VRTX, REGN, MRNA, ARGX, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SCNI
Scinai Immunotherapeutics Ltd Adr
|
1.55 | 1.05M | 1.22M | -3.26M | -6.38M | -6.1455 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Scinai Immunotherapeutics Ltd Adr 주식(SCNI)의 최신 뉴스
Full issuance would represent about 66.67% of Scinai (SCNI)'s depositary shares under its funding deal. - Stock Titan
Scinai regains compliance with Nasdaq minimum bid price rule By Investing.com - Investing.com Nigeria
SCNI Stock Wobbles As Scinai Refocuses On NanoAb Platform - timothysykes.com
Scinai regains compliance with Nasdaq minimum bid price rule - Investing.com
Scinai Immunotherapeutics regains Nasdaq compliance - TipRanks
Why Veea Shares Are Trading Higher By 58%; Here Are 20 Stocks Moving Premarket - Benzinga
Why Scholar Rock Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket - Benzinga
Nasdaq Down Over 200 Points; Cellectis Shares Plunge - Benzinga
Scinai Immunotherapeutics (SCNI) Q4 2023 Earnings: Narrower-Than-Expected Loss of $0.47 Per ShareRetail Earnings Report - dars.gov.et
Scinai Immunotherapeutics refocuses capital on NanoAb platform and CDMO business - TipRanks
Scinai Concludes PC111 Arrangements and Refocuses Capital on NanoAb Platform and Growing CDMO Business - Barchart.com
Scinai (NASDAQ: SCNI) updates $15M equity deal that could dilute investors - Stock Titan
Earnings call transcript: Scinai posts H1 2026 revenue growth as losses persist - Investing.com Nigeria
Scinai reports H1 2026 results, announces U.S. customer expansion - Investing.com India
Scinai Immunotherapeutics (NASDAQ: SCNI): Why Is A recent reverse share split that reset the chart structure in Focus Now? - Kalkine Media
What Could Scinai Immunotherapeutics (NASDAQ:SCNI) Reveal Today About Its Next Operating Milestones? - Kalkine Media
Scinai Strengthens CDMO Leadership with Appointment of Eran Kuratz as Head of Supply Chain and Business Process Administration - Barchart.com
SCNIScinai Immunotherapeutics Ltd ADR Latest SEC Filings - Finviz
Scinai Immunotherapeutics Ltd. Sponsored ADR Actuals & Estimates (NASDAQ:SCNI) - TradingView
Price to sales forward of Scinai Immunotherapeutics Ltd. Sponsored ADR – MUN:2F5 - TradingView
Enterprise value to revenue forward of Scinai Immunotherapeutics Ltd. Sponsored ADR – MUN:2F5 - TradingView
Enterprise value to EBITDA forward of Scinai Immunotherapeutics Ltd. Sponsored ADR – MUN:2F5 - TradingView
Enterprise value to EBIT forward of Scinai Immunotherapeutics Ltd. Sponsored ADR – MUN:2F5 - TradingView
Why Scinai Immunotherapeutics stock is skyrocketing 90% higher today - MSN
Scinai Reports First Quarter 2026 Financial Results and Provides Corporate Update Highlighting Expansion of CDMO Platform and Advancement of Strategic Growth Initiatives - Barchart.com
SCNI Technical Analysis | Trend, Signals & Chart Patterns | SCINAI IMMUNOTHERAPEUTICS LT (NASDAQ:SCNI) - ChartMill
Scinai appoints Eilon Elmalem as Yavne CDMO facility head - Investing.com
Scinai appoints Eilon Elmalem as Yavne CDMO facility head By Investing.com - Investing.com India
Scinai Biopharma Services Appoints Eilon Elmalem as Site Head of Yavne CDMO Facility - Barchart.com
Scinai Immunotherapeutics to Lead Strategic Roundtable Discussion on Oral Therapies and the Future of Biologics at the 7th Dermatology Drug Development Summit Europe - Sahm
Scinai Immunotherapeutics to Lead Strategic Roundtable Discussion on Oral Therapies and the Future of Biologics at the 7th Dermatology Drug Development Summit Europe - Benzinga
Scinai Immunotherapeutics schedules annual shareholder meeting for June 16 - Investing.com
NASDAQ gains over 100 points; Intel shares jump after strong Q1 results - MSN
Tangible book value per share of Scinai Immunotherapeutics Ltd. Sponsored ADR – FWB:2F5 - TradingView
Wedge DownStock ScreenerCharts - Finviz
Why Organon Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket - Benzinga
Why Scinai Immunotherapeutics Stock Is Skyrocketing 90% Higher Today - Sahm
Scinai Immunotherapeutics Announces $2.61 Million Private Placement Financing - Finviz
Nasdaq Gains Over 100 Points; Intel Shares Jump After Strong Q1 Results - Benzinga
Scinai raises $2.61M in private placement to expand CDMO unit - Investing.com
Scinai raises $2.61M in private placement to expand CDMO unit By Investing.com - Investing.com South Africa
Why TopBuild Shares Are Trading Higher By 20%; Here Are 20 Stocks Moving Premarket - Sahm
Scinai Completes Corporate Reorganization Separating CDMO and R&D Operations - Contract Pharma
Scinai completes corporate reorganization, separates CDMO unit By Investing.com - Investing.com South Africa
Cash per share of Scinai Immunotherapeutics Ltd. Sponsored ADR – FWB:2F5 - TradingView
Total debt per share of Scinai Immunotherapeutics Ltd. Sponsored ADR – FWB:2F5 - TradingView
Scinai completes corporate reorganization, separates CDMO unit - Investing.com
Scinai Completes Strategic Reorganization to Establish Dedicated CDMO Platform and Lean R&D Structure; Outlines 2026 Priorities - Barchart.com
Scinai Reports Full-Year 2025 Results, with CDMO Revenues Doubling and Strategic Expansion Through Recipharm Collaboration - Sahm
Scinai Immunotherapeutics (NASDAQ: SCNI) details going concern, CDMO and NanoAb risks - Stock Titan
Scinai Immunotherapeutics Highlights Expanded CDMO Platform and Immunology Pipeline at BIO-Europe Spring® 2026 - Barchart.com
Scinai Immunotherapeutics Ltd Adr (SCNI) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.06%
2.55%
자본화:
|
볼륨(24시간):